Clinical Trials in Relapsed Lymphoma: What Patients Should Know

Clinical trials provide patients with relapsed or treatment-resistant lymphoma access to emerging therapies, making conversations with providers essential, according to Dr. Jennifer Effie Amengual, a lymphoma specialist at Columbia University.

Amengual explained that patients should begin by understanding the different types of clinical trials available. These include phase 1 studies, which may involve treatments not yet tested in humans, phase 2 trials that evaluate how well therapies work, and phase 3 trials that compare treatments across patient groups.

She emphasized the importance of asking how a clinical trial fits into a patient’s current treatment plan, as well as what alternative options may be available. Patients should also discuss the expectations tied to participation, including the number of required visits and whether additional procedures, such as blood draws or biopsies, are needed.

Eligibility is another key factor, as some trials are limited to specific cancer subtypes or require certain genetic mutations. Because trials can open and close over time, speaking with a provider can help identify appropriate and timely options.

Amengual noted that when lymphoma returns, there is often no single standard treatment approach. Clinical trials are designed to expand access to promising therapies and help bring new treatment options to patients more quickly.

Transcript

How can patients with relapsed or treatment-resistant lymphoma approach conversations about clinical trials, and what factors should they consider?

Clinical trials offer valuable opportunities to bring the latest treatment approaches to patients, so anyone with relapsed disease should speak with their provider about them. There are many different types of clinical trials, and one important factor to understand is the phase of the study. For example, phase 1 trials may involve drugs that have not yet been tested in humans, while phase 2 trials often evaluate how well a treatment works, sometimes using combinations of already approved drugs. Phase 3 trials may compare treatments by randomly assigning patients to different groups.

Patients should ask how a clinical trial might fit into their current care plan and what alternative treatment options are available. It is also important to understand expectations for participation, such as how many visits are required and whether additional blood draws or biopsies will be needed.

Another key consideration is eligibility. Some trials open and close over time, and others are limited to specific cancer types or patients with certain mutations. Discussing eligibility with a provider can help determine what options may be available.

When lymphoma relapses, there is often no single standard approach to treatment. Clinical trials are designed with patients in mind, aiming to deliver promising therapies more quickly and expand access to new options.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.